A Composite Synergistic Systems Model for Exploring the Efficacies of Different Chemotherapeutic Strategies in Cancer

Table 3

Simulation results in different therapeutic strategies.

Different strategies	VG model				FD model				Condition
	Days	𝑐1	𝑐2	𝑣𝑣	S	R	𝑛(2,2)	𝑐(2,2)
(0) Free growth	50	1.5×10^9	5.6×10^9	9.0×10^4	8.2×10^8	5×10^9	10.47	0.248	Freely growing condition
	150	1.6×10^15	6.1×10^19	7.4×10^6	8.64×10^14	5.40×10^19	11.7864	1.525
	300	1.7×10^24	6.8×10^34	5.43×10^9	9.28×10^23	6.07×10^34	266.23	23.26
	500	1.9×10^36	7.9×10^54	3.6×10^13	1.02×10^36	7.08×10^54	3.65×10^5	879.54
(1a) MTD strategy (conventional dose)	50	3.57×10^6	1.85×10^7	4.74×10^3	1.15×10^7	4.06×10^8	0.039	0.248	Drug application as per Table 1(a), drug cycle = 6
	150	5.65×10^4	6.3×10^9	9.12×10^3	2.76×10^8	3.25×10^16	0.5160	1.525
	300	1.45×10^13	8.36×10^23	6.72×10^6	2.49×10^17	3.47×10^31	204.07	23.26
	500	1.6×10^25	9.76×10^43	4.47×10^10	2.74×10^29	4.05×10^51	2.92×10^5	879.54
(1b) MTD strategy (high dose)	50	3.22×10^6	1.7×10^7	4.34×10^3	1.07×10^7	3.99×10^8	0.039	0.248	Drug dose = 0.255; other condition is the same as strategy 1a
	150	2.67×10^4	1.9×10^9	7.35×10^3	2.1×10^8	3.02×10^16	0.516	1.525
	300	4.81×10^12	1.41×10^23	5.41×10^6	1.88×10^17	3.22×10^31	204.07	23.257
	500	5.29×10^24	1.64×10^43	3.61×10^10	2.07×10^29	3.75×10^51	3.35×10^5	879.54
(2) MTD with HSC transplantation	50	1.37×10^8	4.42×10^8	3.9×10^5	2.27×10^7	2.99×10^8	0.14	0.248	MTD drug (as per strategy 1a) is applied and HSC transplantation was applied alternatively (total 5 times) after a gap period of 20 days
	150	7.26×10^14	1.71×10^16	6.22×10^7	9.45×10^9	5.22×10^15	0	1.525
	300	1.40×10^23	2.65×10^28	2.16×10^10	1.09×10^15	4.44×10^27	192.53	23.26
	500	1.54×10^35	3.1×10^48	2.27×10^16	1.2×10^27	5.18×10^47	3.59×10^5	879.54
(3) AAG strategy	50	1.8×10^7	1.22×10^7	890.54	3.61×10^7	1.74×10^7	11.1948	0.0834	Applied continuously with a strategy as per Table 1(a)
	150	3.99×10^8	5.88×10^8	29.02	6.68×10^8	6.31×10^8	14.1133	0.0709
	300	2.55×10^10	1.06×10^11	0.08	4.33×10^10	1.15×10^11	19.99	0.0502
	500	6.52×10^12	1.09×10^14	0	1.11×10^13	1.17×10^14	31.84	0.0295
(4) MTD with HSC transplantation followed by AAG	50	1.37×10^8	4.42×10^8	3.9×10^5	2.72×10^7	2.99×10^8	0.14	0.25	MTD with HSC as per strategy 2 and AAG as per strategy 3, AAG started after 8 days of the completion of strategy 2
	150	7.26×10^13	1.71×10^16	6.22×10^7	9.45×10^9	5.22×10^15	0	1.525
	300	3.39×10^23	3.46×10^28	2.83×10^7	3.83×10^12	5.41×10^22	40.18	6.38
	500	1.07×10^35	5.06×10^47	7.36×10^3	9.82×10^14	5.53×10^25	113.03	3.75
(5) MCT (without Im and Ihs)	50	7.71×10^6	5.83×10^7	1.29×10^4	2.88×10^6	1.28×10^7	1.99	0.09	Continuous (daily) application of drug as per Table 1(a) but without Im and Ihs
	150	1.4×10^6	4.25×10^11	8.18×10^3	7.19×10^5	4.13×10^7	1.3045	0.05
	300	3.35×10^4	1.97×10^16	4.09×10^3	1.00×10^3	2.47×10^8	0.0045	0.016
	500	6.29	6.82×10^18	1.63×10^3	0	7.38×10^8	0	0.004
(6) MCT (without Im and Ihs) with intermittent AAG (15-day interval)	50	7.22×10^6	5.50×10^7	1.40×10^4	3.67×10^6	1.41×10^7	2.25	0.10	MCT drug is applied daily as per strategy 5 with AAG application in every 15-day interval as per strategy 3
	150	2.34×10^6	4.76×10^11	1.13×10^4	8.26×10^5	8.82×10^7	1.29	0.057
	300	4.10×10^4	3.75×10^17	8.32×10^3	1.42×10^4	1.43×10^9	0.03	0.026
	500	4.09×10^4	2.73×10^25	5.61×10^3	0	6.38×10^9	0	0.009
(7) MCT (with Im and Ihs) with intermittent AAG	50	5.04×10^6	3.95×10^7	1.04×10^4	2.61×10^6	1.02×10^7	1.66	0.096	MCT drug (having Im and Ihs) is applied, except the day of AAG drug application; AAG is applied with a 15-day interval as per strategy 3
	150	0	0	0	8.83×10^3	5.13×10^3	0.13	0.057
	300	0	0	0	0	0	0	0.026
	500	0	0	0	0	0	0	0.009
(8) MCT strategy (with Im and Ihs)	50	5.40×10^6	4.19×10^7	9.66×10^3	2.05×10^6	8.94×10^6	1.47	0.09	Drug is applied as per strategy 5 and with Im and Ihs
	150	0	0	0	7.73	16.79	0	0.04
	300	0	0	0	0	0	0	0.016
	500	0	0	0	0	0	0	0.004